Eosinophilic Granulomatosis with Polyangiitis: Latest Findings and Updated Treatment Recommendations
Journal of Clinical Medicine · 15.09.2023 · 12 (18) · 5996
DOI: 10.3390/jcm12185996 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 15.09.2023. Verfasst von Ryu Watanabe und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI, a grant-in-aid of the Cardiovascular Research Fund, Tokyo, Japan, Cardiovascular Research Fund, Tokyo, Japan.
Abstract (Originalsprache)
Eosinophilic granulomatosis with polyangiitis (EGPA) causes necrotizing vasculitis and eosinophil-rich granulomatous inflammation in small- to medium-sized vessels, resulting in multiple organ damage. EGPA is classified as an antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, with myeloperoxidase-ANCA detected in approximately one-third of the patients. Conventional treatment of EGPA relies on systemic glucocorticoids (GCs) in combination with cyclophosphamide when poor prognostic factors are present; however, the dilemma between disease control and drug-related adverse effects has long been a challenge. Recent studies have revealed that the genetic background, pathophysiology, and clinical manifestations differ between ANCA-positive and ANCA-negative patients; however, mepolizumab, an interleukin (IL)-5 inhibitor, is effective in both groups, suggesting that the IL-5-eosinophil axis is deeply involved in the pathogenesis of both ANCA-positive and ANCA-negative EGPA. This review summarizes the latest knowledge on the pathophysiology of EGPA and focuses on the roles of eosinophils and ANCA. We then introduce the current treatment recommendations and accumulated evidence for mepolizumab on EGPA. Based on current unmet clinical needs, we discuss potential future therapeutic strategies for EGPA.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.
ORCID-Profile: Ryu Watanabe
Förderung
- JSPS KAKENHI
- a grant-in-aid of the Cardiovascular Research Fund, Tokyo, Japan
- Cardiovascular Research Fund, Tokyo, Japan
Zitieren
APA
Watanabe, R., & Hashimoto, M. (2023). Eosinophilic Granulomatosis with Polyangiitis: Latest Findings and Updated Treatment Recommendations. Journal of Clinical Medicine, 12(18), 5996. https://doi.org/10.3390/jcm12185996
Vancouver
Watanabe R, Hashimoto M. Eosinophilic Granulomatosis with Polyangiitis: Latest Findings and Updated Treatment Recommendations. Journal of Clinical Medicine. 2023;12(18):5996. doi:10.3390/jcm12185996
BibTeX
@article{Watanabe2023,
author = {Watanabe, Ryu and Hashimoto, Motomu},
title = {Eosinophilic Granulomatosis with Polyangiitis: Latest Findings and Updated Treatment Recommendations},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {18},
pages = {5996},
doi = {10.3390/jcm12185996}
}
EUVIMED